(Q36755500)

16 August 2017

1 reference

title

Update on the molecular biology of malignant mesothelioma (English)

1 reference

16 August 2017

0 references

Amie Y Lee

1

1 reference

16 August 2017

Dan J Raz

series ordinal

2

1 reference

16 August 2017

Biao He

series ordinal

3

1 reference

16 August 2017

David M Jablons

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

109

1 reference

16 August 2017

issue

8

1 reference

16 August 2017

page(s)

1454-1461

1 reference

The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

The European mesothelioma epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Asbestos and the pleura: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

SV40 and human tumours: myth, association or causality?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenic treatments

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Review of epidermal growth factor receptor biology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

EGFR overexpression in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Persistent induction of c-fos and c-jun expression by asbestos

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

The INK4a/ARF network in tumour suppression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Expression of bcl-2 family members in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Tumor suppression by Ink4a-Arf: progress and puzzles

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Alterations of the p16(INK4) locus in human malignant mesothelial tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Inactivation of p16INK4a expression in malignant mesothelioma by methylation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Simian virus-40 large-T antigen binds p53 in human mesotheliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

The expression pattern of beta-catenin in mesothelial proliferative lesions and its diagnostic utilities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Cadherins, catenins and APC in pleural malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Wnt2 as a new therapeutic target in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Involvement of IL-10 and Bcl-2 in resistance against an asbestos-induced apoptosis of T cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22552

7 January 2021

Identifiers

DOI

10.1002/CNCR.22552

1 reference

16 August 2017

1 reference